Overview
Corporate structure
Alamar Biosciences, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Alamar Biosciences, Inc.
- Yuling Luo Filed SCHEDULE 13G on Alamar Biosciences, Inc., latest Aug 13, 2026
- Qiming Corporate GP VI, Ltd. Filed SCHEDULE 13G on Alamar Biosciences, Inc., latest Aug 11, 2026
- Sands Capital Life Sciences Pulse Fund II, L.P. Filed SCHEDULE 13D/A on Alamar Biosciences, Inc., latest Jul 7, 2026 (2 filings since Apr 23, 2026)
- SHERPA HEALTHCARE FUND II, L.P. Filed SCHEDULE 13G on Alamar Biosciences, Inc., latest Jul 2, 2026
- Illumina Innovation Fund II, L.P. Filed SCHEDULE 13D on Alamar Biosciences, Inc., latest Apr 23, 2026
- Alamar Biosciences, Inc. Fremont, California
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
Leadership
Who has led Alamar Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
- Chief executive officerYuling Luo Apr 16, 2026 to now5
- PresidentTimothy Ogden White Apr 16, 2026 to now6
- Chief financial officerJustin J. McAnear Apr 16, 2026 to now7
- Chief operating officerShiping Chen Apr 16, 2026 to now8
Board members and other officers (8)
- Board memberFrank Witney Apr 16, 2026 to now9
- Board memberIan W. Ratcliffe Apr 16, 2026 to now10
- Board memberNicholas Naclerio Apr 16, 2026 to now11
- Board memberRebecca Chambers Apr 16, 2026 to now12
- Board memberShiping Chen Apr 16, 2026 to now8
- Board memberYuling Luo Apr 16, 2026 to now5
- Board memberRobert P. Ragusa Sep 3, 2026 to now13
- General counselJohn L. Brottem Sep 16, 2026 to now14
Timeline
Calendar
Coming up
- Nov 3, 2026 · After the closeReports results for the quarter ending Sep/202620
When it reported results
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
54 filings to the SEC since October 2021: 2 quarterly reports, 5 major events, 23 insider forms, 6 large holders, 18 other. The latest 20:
- Oct 14, 2026144 EDGAR
- Oct 14, 2026144 EDGAR
- Oct 14, 2026144 EDGAR
- Oct 14, 2026144 EDGAR
- Sep 16, 20264 EDGAR
- Sep 16, 20263 EDGAR
- Sep 3, 20264 EDGAR
- Sep 3, 20263 EDGAR
- Sep 1, 20268-K EDGAR
- Aug 13, 2026SCHEDULE 13G EDGAR
- Aug 11, 2026SCHEDULE 13G EDGAR
- Aug 11, 202610-Q EDGAR
- Aug 10, 20268-K EDGAR
- Jul 15, 20268-K EDGAR
- Jul 7, 2026SCHEDULE 13D/A EDGAR
- Jul 2, 2026SCHEDULE 13G EDGAR
- May 8, 202610-Q EDGAR
- May 8, 20268-K EDGAR
- Apr 23, 2026SCHEDULE 13D EDGAR
- Apr 23, 2026SCHEDULE 13D EDGAR
The 54 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 20, 2026 | Naclerio Nicholas10% owner | Buy | 235,294 | $17.00 | $4.0M | Form 4 |
| Apr 20, 2026 | Illumina Innovation Fund II GP, L.L.C.10% owner | Buy | 235,294 | $17.00 | $4.0M | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Yuling LuoSCHEDULE 13G, 1 filing Aug 13, 202621
- Qiming Corporate GP VI, Ltd.SCHEDULE 13G, 1 filing Aug 11, 202622
- Sands Capital Life Sciences Pulse Fund II, L.P.SCHEDULE 13D/A, 2 filings Apr 23, 2026 to Jul 7, 202623
- SHERPA HEALTHCARE FUND II, L.P.SCHEDULE 13G, 1 filing Jul 2, 202624
- Illumina Innovation Fund II, L.P.SCHEDULE 13D, 1 filing Apr 23, 202625
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 86. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Alamar Biosciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARAlamar Biosciences, Inc.1
- CIK0002104204
- Employer ID (EIN)36-48990361
- Filer status<br>emerging growth company1
- Incorporated inDelaware1
- Fiscal year endsDecember 311
- Industry code (SIC)3826 Laboratory Analytical Instruments1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address47071 Bayside Parkway, Fremont, CA 945381
- Phone510-626-98881
- Shares outstanding69,392,766 as of Jul 31, 20263
- On EDGAR sinceJan 9, 20261
- Filings54 in all: 3 (12), 4 (11), 8-K (5), 144 (4), SCHEDULE 13G (3), 10-Q (2), DRS/A (2), EFFECT (2)1
All 19 form types
S-1/A (2), SCHEDULE 13D (2), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), POS AM (1), S-1 (1), S-1MEF (1), S-8 (1), SCHEDULE 13D/A (1)
- Latest filingsQuarterly report (10-Q) Aug 11, 2026
Latest 8-K (8-K) Sep 1, 2026
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5SEC EDGARYuling Luo, Chief executive officer
- 6SEC EDGARTimothy Ogden White, President
- 7
- 8
- 9SEC EDGARFrank Witney, Board member
- 10SEC EDGARIan W. Ratcliffe, Board member
- 11SEC EDGARNicholas Naclerio, Board member
- 12SEC EDGARRebecca Chambers, Board member
- 13SEC EDGARRobert P. Ragusa, Board member
- 14SEC EDGARJohn L. Brottem, General counsel
- 15SEC EDGARExecutive or director change
- 16SEC EDGARResults of operations
- 17SEC EDGAROther events
- 18SEC EDGARResults of operations
- 19
- 20NasdaqNasdaq calendar
- 21
- 22
- 23
- 24
- 25